Compare JBLU & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBLU | CAPR |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2002 | 2011 |
| Metric | JBLU | CAPR |
|---|---|---|
| Price | $5.25 | $34.89 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $4.91 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 26.9M | 946.7K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,062,000,000.00 | N/A |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $6.75 | $3.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.86 | $4.30 |
| 52 Week High | $6.46 | $40.37 |
| Indicator | JBLU | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 61.19 |
| Support Level | $4.74 | $22.09 |
| Resistance Level | $5.66 | $36.49 |
| Average True Range (ATR) | 0.35 | 2.01 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 49.03 | 74.10 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.